Your Messages Inbox
Your Article Summary
See Latest ArticlesNabi Biopharmaceuticals Receives Scientific Advice On NicVAX(r) From the European Medicines Agency
Nabi Biopharmaceuticals, 06/04/09
Nabi Biopharmaceuticals announced it has received scientific advice from the European Medicines Agency on NicVAX regarding the requirements for marketing authorization submission as it relates to the appropriate design of the pivotal phase III clinical studies and safety data base. This advice helps ensure the performance of appropriate clinical studies so that no major objections regarding the design of the studies are likely to be raised during evaluation of the marketing authorization application.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Article Search
Sponsor